Nox-generated ROS modulate glucose uptake in a leukaemic cell line

References

• Iiyama M, Kakihana K, Kurosu T, Miura O. Reactive oxygen species generated by hematopoietic cytokines play roles in activation of receptor-mediated signaling and in cell cycle progression. Cell Signal 2006; 181: 74–82
   Google Scholar
• Goldstein BJ, Mahadev K, Wu X. Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. Diabetes 2005; 4: 311–321
   Google Scholar
• Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 2002; 91: 406–413
   PubMed Web of Science ®Google Scholar
• Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004; 4: 181–189
   PubMed Web of Science ®Google Scholar
• Suh YA, Arnold RS, Lassegue B, Shi J, Xu X, Sorescu D, Chung AB, Griendling KK, Lambeth JD. Cell transformation by the superoxide-generating oxidase Mox1. Nature 1999; 401: 79–82
   PubMed Web of Science ®Google Scholar
• Cheng G, Cao Z, Xu X, van Meir EG, Lambeth JD. Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5. Gene 2001; 269: 131–140
   PubMed Web of Science ®Google Scholar
• Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87: 245–313
   PubMed Web of Science ®Google Scholar
• Fiorentini D, Prata C, Maraldi T, Zambonin L, Hakim G, Landi L. ROS contribution to the regulation of GLUT1 in two hemopoietic cell lines differing in cytokine sensitivity. Free Radic Biol Med 2004; 37: 1402–1411
   PubMedGoogle Scholar
• Hiramatsu A, Miwa H, Shikami M, Ikai T, Tajima E, Yamamoto H, Imai N, Hattori A, Kyo T, Watarai M, Miura K, Satoh A, Itoh M, Imamura A, Mihara H, Katoh Y, Nitta M. Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML. Leuk Lymphoma 2006; 47: 89–95
   PubMed Web of Science ®Google Scholar
• Bonsi L, Pierdomenico L, Biscardi M, Marchionni C, Gavazzi S, Fossati V, Ghinassi B, Alviano F, Rondelli D, Franchina M, Bagnara GP, Grossi A. Constitutive and stimulated production of VEGF by human megakaryoblastic cell lines: effect on proliferation and signaling pathway. Int J Immunopathol Pharmacol 2005; 18: 445–455
   PubMed Web of Science ®Google Scholar
• Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005; 202: 654–662
   PubMed Web of Science ®Google Scholar
• Chiarugi P, Buricchi F. Protein tyrosine phosphorylation and reversible oxidation: two cross-talking posttranslation modifications. Antioxid Redox Signal 2007; 9: 1–24
   PubMed Web of Science ®Google Scholar
• Maraldi T, Rugolo M, Fiorentini D, Landi L, Hakim G. Glucose transport activation in human hematopoietic cells M07e is modulated by cytosolic calcium and calmodulin. Cell Calcium 2006; 4: 373–381
   Google Scholar
• Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248–254
   PubMed Web of Science ®Google Scholar
• Berridge MV, Herst PM, Tan AS. Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 2005; 11: 127–152
   PubMedGoogle Scholar
• Shi H, Liu S, Miyake M, Liu KJ. Ebselen induced C6 glioma cell death in oxygen and glucose deprivation. Chem Res Toxicol 2006; 19: 655–660
   PubMed Web of Science ®Google Scholar
• Ozen S, Akyol O, Iraz M, Sogut S, Ozugurlu F, Ozyurt H, Odaci E, ldirim Z. Role of caffeic acid phenethyl ester, an active component of propolis, against cisplatin-induced nephrotoxicity in rats. J Appl Toxicol 2004; 4: 27–35
   Google Scholar
• Paolini M, Valgimigli L, Marchesi E, Trespidi S, Pedulli GF. Taking EPR ‘snapshots’ of the oxidative stress status in human blood. Free Radic Res 2003; 37: 503–508
   PubMed Web of Science ®Google Scholar
• Henderson LM, Chappel JB. NADPH oxidase of neutrophils. Biochim Biophys Acta 1996; 1273: 87–107
   PubMed Web of Science ®Google Scholar
• Miller AA, Drummond GR, Sobey CG. Novel isoforms of NADPH-oxidase in cerebral vascular control. Pharmacol Ther 2006; 111: 928–948
   PubMed Web of Science ®Google Scholar
• Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci 2004; 101: 7618–7623
   PubMed Web of Science ®Google Scholar
• Gu Y, Xu YC, Wu RF, Souza RF, Nwariaku FE, Terada LS. TNFalpha activates c-Jun amino terminal kinase through p47(phox). Exp Cell Res 2002; 272: 62–74
   PubMedGoogle Scholar
• Knight LA, Di Nicolantonio F, Whitehouse PA, Mercer SJ, Sharma S, Glaysher S, Hungerford JL, Hurren J, Lamont A, Cree IA. The effect of imatinib mesylate (Glivec) on human tumour-derived cells. Anticancer Drugs 2006; 17: 649–655
   PubMedGoogle Scholar
• Kuan YH, Lin RH, Lin HY, Huang LJ, Tsai CR, Tsao LT, Lin CN, Chang LC, Wang JP. Activation of phosphoinositide 3-kinase and Src family kinase is required for respiratory burst in rat neutrophils stimulated with artocarpol A. Biochem Pharmacol 2006; 71: 1735–1746
   PubMedGoogle Scholar
• Arbiser JL, Petros J, Klafter R, Govindajaran B, McLaughlin ER, Brown LF, Cohen C, Moses M, Kilroy S, Arnold RS, Lambeth JD. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci 2002; 99: 715–720
   PubMed Web of Science ®Google Scholar
• Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 2003; 24: 471–478
   PubMed Web of Science ®Google Scholar
• Geiszt M. NADPH oxidases: new kids on the block. Cardiovasc Res 2006; 71: 289–299
   PubMed Web of Science ®Google Scholar
• Arnold RS, Shi J, Murad E, Whalen AM, Sun CQ, Polavarapu R, Parthasarathy S, Petros JA, Lambeth JD. Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc Natl Acad Sci 2001; 98: 550–555
   Google Scholar
• Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP, Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor WR, Griendling KK. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002; 105: 1429–1435
   PubMed Web of Science ®Google Scholar
• Bae YS, Sung JY, Kim OS, Kim YJ, Hur KC, Kazlauskas A, Rhee SG. Platelet-derived growth factor-induced H2O2 production requires the activation of phosphatidylinositol 3-kinase. J Biol Chem 2000; 275: 10527–10531
   PubMed Web of Science ®Google Scholar
• Kanai F, Liu H, Field SJ, Akbary H, Matsuo T, Brown GE, Cantley LC, Yaffe MB. The PX domains of p47phox and p40phox bind to lipid products of PI(3)K. Nat Cell Biol 2001; 3: 675–678
   PubMed Web of Science ®Google Scholar
• Han J, Luby-Phelps K, Das B, Shu X, Xia Y, Mosteller RD, Krishna UM, Falck JR, White MA, Broek D. Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. Science 1998; 279: 558–560
   PubMedGoogle Scholar
• Ushio-Fukai M. VEGF signaling through NADPH oxidase-derived ROS. Antioxid Redox Signal 2007; 9: 731–739
   Google Scholar
• Choi K, Kennedy M, Kazarov A, Papadimitriou J, Keller G. A common precursor for hematopoietic and endothelial cells. Development 1998; 125: 725–732
   PubMed Web of Science ®Google Scholar
• Maraldi T, Prata C, Fiorentini D, Zambonin L, Landi L, Hakim G. Signal processes and ROS production in glucose transport regulation by thrombopoietin and granulocyte macrophage-colony stimulation factor in a human leukaemic cell line. Free Radic Res 2007; 41: 1348–1357
   PubMed Web of Science ®Google Scholar
• Palmada M, Boehmer C, Akel A, Rajamanickam J, Jeyaraj S, Keller K, Lang F. SGK1 kinase upregulates GLUT1 activity and plasma membrane expression. Diabetes 2006; 55: 421–427
   PubMed Web of Science ®Google Scholar
• Halliwell B. Gutteridge JMC. Free radicals in biology and medicine4th ed. Oxford University Press Inc., New York 2007; 187
   Google Scholar
• Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 2004; 104: 1931–1939
   PubMed Web of Science ®Google Scholar
• Johnson DH. Targeted therapies in combination with chemotherapy in non-small cell lung cancer. Clin Cancer Res 2006; 12: 4451–4457
   Google Scholar